Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) BofA Securities 2023 Health Care Conference May 9, 2023 12:20 PM ET Company Participants Charlie Wagner - EVP and CFO David Altshuler - CSO and EVP, Global Research Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the first morning of the BofA Healthcare Conference. I'm Geoff Meacham. I'm the senior biopharma analyst here and we're thrilled to have Vertex Pharmaceuticals in the big room, hopefully no protesting this year. ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Officer Stuart Arbuckle - Executive Vice President and Chief Operating Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - SV8 Securities Mohit Bansal - Wells Fargo Geoff ...

FIRST QUARTER 2023 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX MAY 1, 2023 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR STAT ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Incorporated Registrant's telephone number, including area code (617) 341-6100 Securities registered pursuant to Se ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - Chief Executive Officer and President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Phil Nadeau - Cowen Liisa Bayko - Evercore ISI David Risinger - SVB Robyn Karnauskas - Tru ...

FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX FEBRUARY 7, 2023 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporate ...

VERTEX THE SCIENCE of POSSIBILITY J.P. MORGAN HEALTHCARE CONFERENCE RESHMA KEWALRAMANI, M.D. CEO AND PRESIDENT JANUARY 2023 ©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com | --- | --- | --- | --- | --- | |--------------------------------------------|-------|----------|-------|-------| | | | | | | | SAFE HARBOR STATEMENT & NONGAAP FINANCIAL | | | | | | | | MEASURES | | | | | | | | | | | | | | | | ©2023 Vertex Pharmaceuticals Incorporated | | | | | This presentation contains forward-looking statemen ...

Vertex Pharmaceuticals Conference Call Summary Company Overview - **Company**: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - **Event**: 41st Annual J.P. Morgan Healthcare Conference Call - **Date**: January 9, 2023 Core Industry and Company Strategy - Vertex focuses on scientific innovation to create transformative medicines for serious diseases, particularly in specialty markets [4][3] - The company has successfully launched four medicines for cystic fibrosis (CF) and projects revenue guidance for 2022 between $8.8 billion and $8.9 billion [5][39] Key Points on Cystic Fibrosis (CF) - Updated CF patient population in the U.S., Europe, Australia, and Canada is now 88,000, up from 83,000 in 2021 [9][57] - Vertex aims to have all eligible patients on CFTR modulators, with over 20,000 patients currently not on therapy [11] - TRIKAFTA submission for ages 2 to 5 has been accepted for priority review in the U.S. with a PDUFA date of April 28 [12] - VX-522, an mRNA therapy for CF patients who cannot benefit from CFTR modulators, has received Fast Track designation from the FDA [14] Pipeline and Near-Term Opportunities - Vertex has near-term commercial opportunities in four disease areas: Exa-cel for sickle cell disease and beta thalassemia, VX-548 for acute pain, and the vanzacaftor triple combination for CF [5][15] - Exa-cel is positioned to be the first approved gene editing therapy for any disease, with a projected lifetime cost of $4 million to $6 million for sickle cell disease [16][15] - VX-548 is a NAV 1.8 inhibitor targeting acute pain, with a market size of approximately $4 billion in the U.S. [26][21] Clinical Development and Regulatory Updates - VX-548 has been granted fast track and breakthrough therapy designations by the FDA [26] - Inaxaplin (VX-147) is in Phase 2/3 trials for APOL1-mediated kidney disease, with a 47.6% reduction in proteinuria demonstrated in earlier studies [30][31] - The VX-880 program for Type 1 diabetes has shown proof of concept with improvements in hemoglobin A1C and C-peptide levels [33] Financial Profile and Investment Strategy - Vertex maintains a strong financial profile with a focus on reinvesting in innovation, having repurchased approximately $1.5 billion in shares over the last two years [44][39] - The company aims to balance internal and external innovation, with 40% of its pipeline resulting from business development activities [38] Competitive Landscape and Future Outlook - The vanzacaftor triple combination is expected to outperform TRIKAFTA based on laboratory and Phase 2 data [61][62] - Vertex is actively engaging with payers and policymakers regarding pricing and reimbursement strategies for Exa-cel [46][48] - The company is preparing for multiple product launches in the next five years, with a goal of five launches in total [8][41] Additional Insights - The company is addressing the treatment gap in acute pain management, where current options are limited and often associated with abuse potential [24][25] - Vertex is working on increasing awareness and diagnosis of APOL1-mediated kidney disease, which affects about 100,000 people in the U.S. and EU [32][33] This summary encapsulates the key points discussed during the Vertex Pharmaceuticals conference call, highlighting the company's strategic focus, pipeline developments, financial outlook, and competitive positioning in the biotechnology industry.

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Ph ...